Richard Scott Struthers - 09 Nov 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: President & CEO, Director
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 09 Nov 2023
Transactions value $: $95,500
Form type: 4
Filing time: 13 Nov 2023, 16:33:30 UTC
Previous filing: 06 Nov 2023
Next filing: 14 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Options Exercise	$95.5K	+50K	+36.89%	$1.91^*	186K	09 Nov 2023	Direct
holding	CRNX	Common Stock						631K	09 Nov 2023	By Family Trust 1
holding	CRNX	Common Stock						1K	09 Nov 2023	By Spouse
holding	CRNX	Common Stock						90K	09 Nov 2023	By Family Trust 2
holding	CRNX	Common Stock						90K	09 Nov 2023	By Family Trust 3
holding	CRNX	Common Stock						90K	09 Nov 2023	By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Incentive stock option (Right to Buy)	Options Exercise	$0	-50K	-33.05%	$0.00	101K	09 Nov 2023	Common Stock	50K	$1.91	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to the option vested on April 16, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.